CAR-T Axi-cel: la terapia personalizzata che sta cambiando l’onco-ematologia

CAR-T therapies represent one of the greatest revolutions in modern hematology and oncology. In this report from the 52nd SIE Congress, discover what Axi-cel is, how personalized CAR-T cell production works, and why reducing manufacturing times can make a difference in the survival of patients with aggressive lymphoma. Let's talk about: • What is Axi-cel CAR-T therapy and how does it work? • CAR-T production in Italy: timing, quality, reliability • Why reducing brain-to-vein syndrome improves patient survival. • Where are CAR-Ts produced in Italy and which centers are authorized? • How rapid manufacturing is changing patient management. • What are FlexiKits and why are they revolutionizing lymphocytopheresis? • Second-line CAR-Ts: advantages for patients with refractory lymphomas. • What is the impact of manufacturing on outcome and complete remission? Axi-cel CAR-T therapy is already available in Italy for some forms of lymphoma and trains the patient's T cells to recognize and destroy tumor cells expressing the CD19 protein. Thanks to recent advances, production is now faster, more reliable, and increasingly closer to 100% first-time success. Reducing production times—from collection to reinfusion—means reducing exposure to bridging therapies, anticipating treatment, and increasing the likelihood of complete remission. This is why manufacturing optimization is considered one of the most strategic clinical aspects for the future of CAR-T. Among upcoming innovations, the new FlexiKits will allow centers to schedule lymphocytopheresis within 24 hours, further accelerating the "brain-to-vein" process and improving hospital organization. This evolution affects not only the technology, but the entire patient journey: from cell collection to the concrete possibility of recovery. 🔔 If you're interested in innovative therapies in hematology and want to stay updated on the new frontiers of CAR-T, subscribe to the channel and activate the bell to never miss upcoming videos. #CAR-T #AxiCel #Lymphoma #Hematology #InnovativeTherapies Interviews with: Francesca Casadei, hematologist – IRCCS Romagna Scientific Institute for the Study and Treatment of Cancer (IRST); Elena Bramanti, hematologist – A. Gemelli University Hospital IRCCS. ********************* 🔥 Follow us! WebTV: https://PianetaSalute.TV Magazine: https://www.PianetaSalute.online Instagram:   / pianetasalute2.0   Twitter:   / pianetasalute   Facebook:   / pianetasalute   Linkedin:   / pianeta-salute-tv   WhatsApp: https://whatsapp.com/channel/0029VaDP... Telegram: https://t.me/pianetasalute Digital terrestrial: National channel 221 Pianeta Salute TV (0:00) - Introduction to the SIE Congress and focus on CAR-T (0:19) - How Axi-cel therapy works and personalization (0:48) - Availability and potential of Axi-cel in Italy (1:14) - Evolution of Axi-cel manufacturing in Italy (1:38) - Improvements in production process times and quality (2:20) - Benefits of early use of Axi-cel (2:56) - Introduction of FlexiKits to optimize production (3:52) - Impact of reduced lead times on treatment and patient outcomes